Amgen's move follows the lifting of a temporary injunction on the launch of its Pavblu-branded biosimilar by the US Court of ...

Amgen AMGN will report third-quarter 2024 results on Oct. 30, after market close. In the last reported quarter, the company ...

On Tuesday, Amgen Inc (AMGN) stock saw a modest uptick, ending the day at $319.66 which represents a slight increase of $2.92 or 0.92% from the prior close of $316.74. The stock opened at $315.24 and ...

Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced that it has entered ...

Genentech, the biotech unit of Swiss major Roche, has been marketing lung cancer drugs for nearly two decades, starting with ...

Ionis has five FDA-approved drugs and promising upcoming approvals. See more about IONS stock and why it warrants a Buy ...

The latest trading session saw Amgen (AMGN) ending at $314.90, denoting a -1.49% adjustment from its last day's close. The stock's performance was behind the S&P 500's daily loss of 0.92%. On the ...

Calling the decision not to disclose the genetic results “certainly troubling” and “ethically fraught,” George Perry, editor ...

Novo Nordisk and Eli Lilly still have first-mover advantage, but Roche, Pfizer and others all have similar products in the ...

The PDUFA dates have been pushed for sotorasib and obeticholic acid for metastatic colorectal cancer and primary biliary ...

A new study from Washington University School of Medicine in St. Louis suggests that a type of immunotherapy -; similar to that approved by the Food and Drug Administration (FDA) to treat inflammatory ...